Hepatobiliary MR imaging with gadolinium-based contrast agents
- PMID: 22334493
- PMCID: PMC3281562
- DOI: 10.1002/jmri.22833
Hepatobiliary MR imaging with gadolinium-based contrast agents
Abstract
The advent of gadolinium-based "hepatobiliary" contrast agents offers new opportunities for diagnostic magnetic resonance imaging (MRI) and has triggered great interest for innovative imaging approaches to the liver and bile ducts. In this review article we discuss the imaging properties of the two gadolinium-based hepatobiliary contrast agents currently available in the U.S., gadobenate dimeglumine and gadoxetic acid, as well as important pharmacokinetic differences that affect their diagnostic performance. We review potential applications, protocol optimization strategies, as well as diagnostic pitfalls. A variety of illustrative case examples will be used to demonstrate the role of these agents in detection and characterization of liver lesions as well as for imaging the biliary system. Changes in MR protocols geared toward optimizing workflow and imaging quality are also discussed. It is our aim that the information provided in this article will facilitate the optimal utilization of these agents and will stimulate the reader's pursuit of new applications for future benefit.
Copyright © 2011 Wiley-Liss, Inc.
Figures
















Similar articles
-
A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.Can Assoc Radiol J. 2017 Aug;68(3):293-307. doi: 10.1016/j.carj.2016.10.008. Epub 2017 Jun 2. Can Assoc Radiol J. 2017. PMID: 28583364 Review.
-
Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.Radiology. 2010 Nov;257(2):589. doi: 10.1148/radiol.101172. Radiology. 2010. PMID: 20959554 No abstract available.
-
Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.Radiographics. 2009 Oct;29(6):1725-48. doi: 10.1148/rg.296095515. Radiographics. 2009. PMID: 19959518
-
Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.Eur Radiol. 2012 Mar;22(3):642-53. doi: 10.1007/s00330-011-2302-4. Epub 2011 Oct 9. Eur Radiol. 2012. PMID: 21984449
-
Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.Radiographics. 2011 Oct;31(6):1547-68. doi: 10.1148/rg.316115528. Radiographics. 2011. PMID: 21997981 Review.
Cited by
-
Is there added value of the hepatobiliary phase of MRI with hepatobiliary contrast agents for hepatocellular carcinoma diagnosis? A meta-analysis.Pol J Radiol. 2024 Aug 19;89:e402-e413. doi: 10.5114/pjr/189614. eCollection 2024. Pol J Radiol. 2024. PMID: 39257926 Free PMC article.
-
Diagnosis of intrahepatic cholangiocarcinoma with CEUS.J Ultrason. 2024 Feb 27;24(96):20240005. doi: 10.15557/jou.2024.0005. eCollection 2024 Feb. J Ultrason. 2024. PMID: 38419841 Free PMC article. Review.
-
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma.JHEP Rep. 2020 Aug 24;2(6):100173. doi: 10.1016/j.jhepr.2020.100173. eCollection 2020 Dec. JHEP Rep. 2020. PMID: 33103093 Free PMC article.
-
Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.Radiol Med. 2014 Jun;119(6):367-76. doi: 10.1007/s11547-013-0364-x. Epub 2013 Dec 3. Radiol Med. 2014. PMID: 24297598
-
Imaging cholangiocarcinoma: CT and MRI techniques.Abdom Radiol (NY). 2025 Jan;50(1):94-108. doi: 10.1007/s00261-024-04216-9. Epub 2024 Jun 25. Abdom Radiol (NY). 2025. PMID: 38916614 Review.
References
-
- de Haen C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TR-rats. Acad Radiol. 1996;3(Suppl 2):S452–454. - PubMed
-
- Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol. 1999;6(5):282–291. - PubMed
-
- Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32(12):780–796. - PubMed
-
- Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol. 2009;50(7):709–715. - PubMed
-
- Package Insert. Teslascan (Mangafodipir trisodium)
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical